Tyrosine hydroxylase inhibitors for treatment of aortic aneurysm

Summary of the technology

Tyrosine hydroxylase inhibitors for treatment of aortic aneurysm
CSIC and the Research Institute of the Hospital de la Santa Creu i Sant Pau (HSCSP-IR) have found the
potential of tyrosine hydroxylase inhibitors for prevention and treatment of aortic aneurysm reducing
aortic damage.
Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent
licence agreement.
An offer for Patent Licensing

CSIC - Consejo Superior de Investigaciones Científicas

Reduction of aneurysm progression

Prevention by AMPT of aortic aneurysms induced by angiotensin II infusion (Ang II) in transgenic mice that over-expresses the NR4A3 receptor.
Images of fixed samples (upper panel) and ultrasound frames of abdominal aortas showing aortic diameter (lower panel).
Aortic aneurysm is a silent but life-threatening vascular disease with no preventive or medical treatment available, apart from surgical repair. It is associated with hypertension, atherosclerosis, ageing and smoking and characterized by chronic inflammation and aortic vessel wall weakening until rupture, causing patient’s death. Different types of aneurysm can be found depending of their anatomic location being Abdominal Aortic Aneurysm (AAA) one of the most common forms.
Recently it has been discovered the upregulation of tyrosine hydroxylase enzyme in human AAA. Presented here is the use of tyrosine hydroxylase inhibitors, particularly α-methyl-p-tyrosine (AMPT), to reduce the progression and severity of aortic aneurysms. This compound has been tested in two mice models (TgNR4A3 transgenic and apoliprotein E- deficient ( ApoE −/−)), significantly reducing vessel inflammation after aneurysm induction with angiotensin II and limiting structural alteration, near to normal levels after treatment during 28 days.
Tyrosine hydroxylase inhibitors show potential for pharmacological prevention and treatment of abdominal and thoracic aortic aneurysm by reduction of aorta dilatation and vessel weakening.

Main innovations and advantages

· AMPT, acting as tyrosine hydroxylase inhibitor, has shown significant effectivity in:
 reducing the incidence and severity of · AAA,  preventing disruption and rupture of elastic vessel laminas,  limiting the inflammatory infiltrate produced by · Ang II.
· Tyrosine hydroxylase inhibitors may represent a promising approach to overcome human aneurysm progression, reducing the risk of aneurysm rupture and death and avoiding surgery and its associated perioperative risk.

Intellectual property status

  • Granted Patent
  • Patent application number :-

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Therapeutic
  • Genetic Engineering / Molecular Biology
  • inhibitors

About CSIC - Consejo Superior de Investigaciones Científicas

The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.

It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.

CSIC - Consejo Superior de Investigaciones Científicas

Never miss an update from CSIC - Consejo Superior de Investigaciones Científicas

Create your free account to connect with CSIC - Consejo Superior de Investigaciones Científicas and thousands of other innovative organizations and professionals worldwide

CSIC - Consejo Superior de Investigaciones Científicas

Send a request for information
to CSIC - Consejo Superior de Investigaciones Científicas

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support